

to use the lowest dose that adequately controls blood glucose. Avoid where possible in severe renal impairment.

- **PATIENT AND CARER ADVICE** The risk of hypoglycaemia associated with sulfonylureas should be discussed with the patient, especially when concomitant glucose-lowering drugs are prescribed.

Driving and skilled tasks Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems.

Glibenclamide

F 747

16-Dec-2019

● INDICATIONS AND DOSE

Type 2 diabetes mellitus

► BY MOUTH USING TABLETS

- Adult: Initially 5 mg daily, adjusted according to response, dose to be taken with or immediately after breakfast; maximum 15 mg per day
- Elderly: 2.5 mg daily, adjusted according to response, dose to be taken with or immediately after breakfast; maximum 15 mg per day

- **UNLICENSED USE** Not licensed for use in breast feeding women with pre-existing diabetes. Not licensed for use in gestational diabetes.
- **CONTRA-INDICATIONS** Avoid where possible in Acute porphyrias p. 1120
- **INTERACTIONS** → Appendix 1: sulfonylureas
- **SIDE-EFFECTS** Appetite abnormal · bone marrow disorders · epigastric discomfort · erythema nodosum · fever · gastrointestinal disorder · hyper eosinophilia · SIADH · Stevens-Johnson syndrome · taste metallic · vision disorders · weight increased
- **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes.
- **BREAST FEEDING** Glibenclamide can be used during breast-feeding in women with pre-existing diabetes.
- **MEDICINAL FORMS** No licensed medicines listed.

F 747

Gliclazide

10-Mar-2020

● INDICATIONS AND DOSE

Type 2 diabetes mellitus

► BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: Initially 40–80 mg daily, adjusted according to response, increased if necessary up to 160 mg once daily, dose to be taken with breakfast, doses higher than 160 mg to be given in divided doses; maximum 320 mg per day

► BY MOUTH USING MODIFIED-RELEASE MEDICINES

- Adult: Initially 30 mg daily, dose to be taken with breakfast, adjust dose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120 mg per day

DOSE EQUIVALENCE AND CONVERSION

- Gliclazide modified release 30 mg may be considered to be approximately equivalent in therapeutic effect to standard formulation gliclazide 80 mg.

- **CONTRA-INDICATIONS** Avoid where possible in Acute porphyrias p. 1120
- **INTERACTIONS** → Appendix 1: sulfonylureas
- **SIDE-EFFECTS** Anaemia · angioedema · dyspepsia · gastrointestinal disorder · hypersensitivity vasculitis ·

hyponatraemia · severe cutaneous adverse reactions (SCARs)

- **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
- **BREAST FEEDING** Avoid—theoretical possibility of hypoglycaemia in the infant.
- **RENAL IMPAIRMENT** If necessary, gliclazide which is principally metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

► Bilxona (Accord Healthcare Ltd)

Gliclazide 30 mg Bilxona 30mg modified-release tablets |

28 tablet [PoM](#) £1.63 DT = £2.81 | 56 tablet [PoM](#) £3.27

Gliclazide 60 mg Bilxona 60mg modified-release tablets |

28 tablet [PoM](#) £3.27 DT = £4.77 | 56 tablet [PoM](#) £6.55

► Dacadis MR (Mylan)

Gliclazide 30 mg Dacadis MR 30mg tablets | 28 tablet [PoM](#) £2.81

DT = £2.81 | 56 tablet [PoM](#) £5.62

► Diamicon MR (Servier Laboratories Ltd)

Gliclazide 30 mg Diamicon 30mg MR tablets | 28 tablet [PoM](#)

£2.81 DT = £2.81 | 56 tablet [PoM](#) £5.62

► Edicil MR (Teva UK Ltd)

Gliclazide 30 mg Edicil MR 30mg tablets | 28 tablet [PoM](#) £2.62 DT

= £2.81 | 56 tablet [PoM](#) £5.24

► Laaglyda MR (Consilient Health Ltd)

Gliclazide 60 mg Laaglyda MR 60mg tablets | 28 tablet [PoM](#) £4.77

DT = £4.77

► Lamzarin (Key Pharmaceuticals Ltd)

Gliclazide 30 mg Lamzarin 30mg modified-release tablets |

28 tablet [PoM](#) £2.81 DT = £2.81 | 56 tablet [PoM](#) £5.62

Gliclazide 60 mg Lamzarin 60mg modified-release tablets |

28 tablet [PoM](#) £4.77 DT = £4.77

► Nazdol MR (Consilient Health Ltd)

Gliclazide 30 mg Nazdol MR 30mg tablets | 28 tablet [PoM](#) £2.35 DT

= £2.81 | 56 tablet [PoM](#) £4.92

► Vamju (Advanz Pharma)

Gliclazide 30 mg Vamju 30mg modified-release tablets |

28 tablet [PoM](#) £1.64 DT = £2.81 | 56 tablet [PoM](#) £3.28

Gliclazide 60 mg Vamju 60mg modified-release tablets |

28 tablet [PoM](#) £3.28 DT = £4.77

► Ziclasge (Lupin Healthcare (UK) Ltd)

Gliclazide 30 mg Ziclasge 30mg modified-release tablets |

28 tablet [PoM](#) £2.38 DT = £2.81 | 56 tablet [PoM](#) £4.77

► Zicron PR (Bristol Laboratories Ltd)

Gliclazide 30 mg Zicron PR 30mg tablets | 28 tablet [PoM](#) £1.95 DT

= £2.81 | 56 tablet [PoM](#) £3.90

Tablet

► Gliclazide (Non-proprietary)

Gliclazide 40 mg Gliclazide 40mg tablets | 28 tablet [PoM](#) £3.19 DT

= £1.51

Gliclazide 80 mg Gliclazide 80mg tablets | 28 tablet [PoM](#) £1.80 DT

= £1.07 | 60 tablet [PoM](#) £0.81-£2.29

► Diamicon (Servier Laboratories Ltd)

Gliclazide 80 mg Diamicon 80mg tablets | 60 tablet [PoM](#) £4.38

► Zicron (Bristol Laboratories Ltd)

Gliclazide 40 mg Zicron 40mg tablets | 28 tablet [PoM](#) £3.36 DT =

£1.51

F 747

Glimepiride

27-Feb-2020

● INDICATIONS AND DOSE

Type 2 diabetes mellitus

► BY MOUTH

- Adult: Initially 1 mg daily, adjusted according to response, then increased in steps of 1 mg every 1–2 weeks, increased to 4 mg daily, dose to be taken shortly before or with first main meal, the daily dose